Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05827016 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
A Phase 3 study of Multiple Myeloma, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,216
- Enrollment target
- 20
- Study locations
NCT05827016 is a Phase 3 study of Multiple Myeloma that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 1,216 participants, above the 544-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (124% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT05827016, a Phase 3 study of Multiple Myeloma, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,216 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Iberdomide
Study Locations (20)
Florida
- Mayo Clinic Florida - Jacksonville
- Tampa General Hospital - Tampa
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
- Cleveland Clinic - Weston
Georgia
- University Cancer Blood Ctr - Athens
- The Winship Cancer Institute of Emory University - Atlanta
- Augusta University - Georgia Cancer Center - Augusta
Michigan
- University of Michigan - Rogel Cancer Center - Ann Arbor
- Henry Ford Health System - The Henry Ford Cancer Institute (HFCI) - Detroit - Detroit
- Cancer & Hematology Centers of Western Michigan (CHCWM) - Grand Rapids
New York
- Local Institution - 0328 - Brooklyn
- Perlmutter Cancer Center at NYU Langone Hematology Oncology Associates-Mineola - Mineola
Colorado
- Rocky Mountain Cancer Centers - Aurora
Illinois
- The University of Chicago Medical Center - Duchossois Center for Advanced Medicine - Chicago
Kansas
- University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care Pavilion - Westwood
Maryland
- Maryland Oncology Hematology, PA- Clinton - Clinton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,216 participants |
| Start Date | 2023-06-22 |
| Est. Completion | 2036-01-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05827016
The ClinicalTrials.gov registry entry for NCT05827016 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,216 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 544-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (124% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Lenalidomide is the first listed.
NCT05827016 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Georgia, Michigan.
Frequently Asked Questions
What is clinical trial NCT05827016 about?
NCT05827016 is a clinical study titled "A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma". The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
What is the current status of trial NCT05827016?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,216 participants. The study started on 2023-06-22. Estimated completion is 2036-01-01.
What conditions does trial NCT05827016 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05827016?
The interventions under investigation include: Lenalidomide (DRUG), Iberdomide (DRUG).
Who is sponsoring clinical trial NCT05827016?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05827016 being conducted?
This trial has 20 study locations across Colorado, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.